Recurrent Thyroid Cancer Clinical Trial
Official title:
A Phase II Study of Single Agent Depsipeptide (FK228) in Radioiodine (RAI)-Refractory Metastatic Non-medullary (Papillary, Follicular, and Hurthle Cell Variants) Thyroid Carcinoma
This phase II trial is studying how well romidepsin works in treating patients with recurrent and/or metastatic thyroid cancer that has not responded to radioactive iodine. Romidepsin may stop the growth of tumor cells by blocking the some of the enzymes needed for cell growth. It may also help radioactive iodine and chemotherapy work better by making tumor cells more sensitive to the drug
Status | Completed |
Enrollment | 20 |
Est. completion date | August 2009 |
Est. primary completion date | August 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed non-medullary thyroid carcinoma, including the following cell types: - Papillary - Follicular - Variants of papillary or follicular - Hürthle cell - Recurrent and/or metastatic disease - Measurable disease - At least 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan - Progressive disease during or after prior treatment, as defined by >= 1 of the following criteria: - Presence of new or progressive lesions on CT scan or MRI - New lesions on bone or positron-emission tomography scan - Rising thyroglobulin level - Minimum of 3 consecutive rises with an interval of >= 1 week between each determination - Refractory to radioactive iodine (RAI) - Absent or insufficient RAI-uptake documented by whole-body RAI scan within the past 6 months - At least 1 lesion with absent RAI-uptake required for insufficient uptake - No known brain metastases - Performance status - Karnofsky 60-100% - WBC >= 3,000/mm^3 - Absolute neutrophil count >= 1,500/mm^3 - Platelet count >= 100,00/mm^3 - Bilirubin normal - AST and ALT =< 2.5 times upper limit of normal - Chronic active viral hepatitis allowed provided patient is clinically stable and fulfills liver function eligibility criteria - Creatinine normal - Creatinine clearance >= 60 mL/min - QTc =< 480 msec by ECG - ST segment depression < 2 mm - LVEF >= 50 % by echocardiogram - No left ventricular hypertrophy, as defined by end-diastolic wall thickness > 12 mm in both the left ventricular posterior wall as well as septum or restrictive cardiomyopathy - No history of any of the following cardiac diseases: - Canadian Cardiovascular Society (CCS) class II-IV angina pectoris - Myocardial infarction within the past 12 months - Sustained ventricular tachycardia, ventricular fibrillation, Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator - Any cardiac arrhythmia requiring digitalis or another antiarrhythmic medication other than a beta blocker or calcium channel blocker - No uncontrolled hypertension (i.e., blood pressure >= 160/95) - Mobitz II second degree block in patients who do not have a pacemaker - First degree or Mobitz I second degree block, bradyarrhythmias or sick sinus syndrome require Holter monitoring and evaluation by cardiology - Uncontrolled dysrhythmias - No history of congenital long QT syndrome - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Thyroid stimulating hormone normal or suppressed - No history of allergic reaction attributed to compounds of similar chemical or biologic composition to FR901228 - No ongoing or active infection - No psychiatric illness or social situation that would preclude study participation - No other concurrent uncontrolled illness - At least 4 weeks since prior biologic or targeted agents (e.g., interferon alfa, thalidomide, octreotide, or cetuximab) - No concurrent antineoplastic biologic agents - No prior FR901228 (depsipeptide) - No prior cytotoxic chemotherapy - Cytotoxic chemotherapy as a radiosensitizer allowed provided >= 3 months since prior administration - No other concurrent antineoplastic chemotherapy - Not specified - At least 4 weeks since prior external beam radiation therapy - Documented disease progression required if patient received external beam radiotherapy to index lesions - At least 3 months since prior RAI therapy - Diagnostic studies using =< 12 mCi of RAI are not considered RAI therapy - No concurrent antineoplastic radiotherapy - At least 2 weeks since prior anticancer cyclooxygenase-2 (COX-2) inhibitors, isotretinoin, or complementary medications - At least 4 weeks since prior tyrosine kinase inhibitors (e.g., gefitinib or erlotinib) - No other concurrent investigational agents - No other concurrent anticancer therapy - No concurrent drugs known to have histone deacetylase inhibitor activity (e.g., valproic acid) - No concurrent combination anti-retroviral therapy for HIV-positive patients - No concurrent hydrochlorothiazide - No concurrent treatment dose warfarin - No concurrent agents that cause QTc prolongation - Concurrent daily aspirin given after myocardial infarction or COX-2 inhibitors at standard anti-inflammatory or pain doses allowed |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan-Kettering Cancer Center at Suffolk | Commack | New York |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumor Major Response Rate (Including Stable Disease) as Measured by RECIST Criteria | From start of treatment to 8 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02152137 -
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
Terminated |
NCT00095693 -
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00470496 -
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
|
Phase 1 | |
Active, not recruiting |
NCT01723202 -
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00085293 -
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
|
Phase 2 | |
Recruiting |
NCT04892303 -
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
|
Phase 1 | |
Terminated |
NCT00126568 -
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00519896 -
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
|
Phase 2 | |
Completed |
NCT01502410 -
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
|
Phase 2 | |
Completed |
NCT01413113 -
Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00134043 -
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00118248 -
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
|
Phase 2 | |
Completed |
NCT00104871 -
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
|
Phase 2 | |
Completed |
NCT00068497 -
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00004074 -
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
|
Phase 1 |